BioCryst Pharmaceuticals, Inc. · NASDAQ:BCRX

BioCryst Pharmaceuticals — Q1 2023 Earnings Presentation

7 slides from BioCryst Pharmaceuticals's earnings presentation, May 3, 2023

  1. Slide 1: First Quarter 2023 Results Call

    First Quarter 2023 Results Call Corporate Update & Financial Results May 3, 2023

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements BioCryst’s presentation may contain forward-looking statements, including statements regarding future results, unaudited and forward-looking financial information and company performance or achievements. These statements are subject to known and unknown risks and uncertain

  3. Slide 3: Agenda

    Agenda ◆ Corporate Update: Jon Stonehouse – President and Chief Executive Officer ◆ Financial Update: Anthony Doyle – Chief Financial Officer ◆ Pipeline Update: Dr. Helen Thackray – Chief Research and Development Officer ◆ ORLADEYO® (berotralstat) Launch Update: Charlie Gayer – Chief Commercial Offi

  4. Slide 4: Strong Underlying Demand Driving ORLADEYO Growth

    Strong Underlying Demand Driving ORLADEYO® Growth Patients on Therapy (US) • ORLADEYO® revenue $68.4M (+38% vs Q1 2022) ~1,000 • Start forms +20% y/y +46% • Retention rate remains stable at 60% through 1 year, with limited discontinuations beyond that • Reimbursement dynamics improving • Launched in

  5. Slide 5: Debt Refinancing: Better Terms, Longer Maturity, Larger Principal

    Debt Refinancing: Better Terms, Longer Maturity, Larger Principal New Terms (Pharmakon) Prior Terms (Athyrium) Principal Drawn $300M $200M Tranches Available $150M None (at company option) (through September 2024) 3 mo. SOFR + 7.00% 3 mo. LIBOR (3.50% cap) + 8.25% Rate With PIK option: +7.25% With P

  6. Slide 6: Finance Summary

    Finance Summary (figures in millions) Q1 2023 Cash Position Cash, cash equivalents, restricted cash & investments at December 31, 2022 $444 Cash, cash equivalents, restricted cash & investments at March 31, 2023 $403 Senior credit facility A $241 Pro forma cash, cash equivalents, restricted cash & i

  7. Slide 7: First Quarter 2023 Results Call

    First Quarter 2023 Results Call Corporate Update & Financial Results May 3, 2023

BioCryst Pharmaceuticals — Q1 2023 Earnings Presentation on 6ix